Big corporate influence on an EU health law may have helped land the European Commission at the receiving end of Europe's top court in Luxembourg.
On Wednesday (16 December), the General Court in Luxembourg ruled against the Brussels-executive for not following the very rules it is meant to enforce.
Sweden took the commission to court for failing to come up with scientific criteria which determine endocrine-disrupting properties.
The General Court ruling can be appealed with...
Enjoy access to all articles and 25 years of archives, comment and gift articles. Become a member for as low as €1,75 per week.
Already a member? Login